Phosphoric Acid

Phosphoric Acid

SCHEMBL122808

O.O.O=P([O-])([O-])[O-].[Na+].[Na+].[Na+]

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
SLC34A1 Q06495 1/20 0.42
KDM4E B2RXH2 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
CA1 P00915 2/20 0.33
CA4 P22748 2/20 0.33
CA5A P35218 2/20 0.33
CA5B Q9Y2D0 2/20 0.33
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
ALOX12 P18054 1/20 0.32
NFKB1 P19838 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL1396195 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL735586 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1076271 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL156385 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL1804580 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL734680 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL232957 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL736397 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL2020039 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A
Phosphoric Acid SCHEMBL14760076 1.00 LMNA (0.43) LMNASLC34A1KDM4ECYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3347043-B1 PROCESS FOR PREPARING AN ATTENUATED TETRAVALENT DENGUE VACCINE FUND BUTANTAN (BR) 2026-01-07 EP claimed
US-20250275531-A1 STABILIZATION MEDIUM FOR EXTENDING TEMPORAL VIABILITY OF HUMAN SEMEN RAMACHANDRAN ASHWIN (AU) 2025-09-04 US claimed
CN-120037189-A Injectable mineralized hydrogel microsphere and preparation method and application thereof 重庆医科大学附属第一医院 2025-05-27 CN claimed
CN-118986017-B Phase-change heat storage heat preservation glove 深圳市心之礼电子有限公司 2025-04-15 CN claimed
WO-2024241345-A1 OPHTHALMIC SUSPENSION COMPOSITION OF BRINZOLAMIDE AND LATANOPROST SENTISS PHARMA PRIVATE LIMITED (IN) 2024-11-28 WO claimed
CN-118986017-A Phase-change heat storage heat preservation glove 深圳市心之礼电子有限公司 2024-11-22 CN claimed
WO-2024121867-A1 PHARMACEUTICAL COMPOSITION FOR GLAUCOMA AND OCULAR HYPERTENSION SENTISS PHARMA PRIVATE LIMITED (IN) 2024-06-13 WO claimed
US-20240147984-A1 COMPOSITIONS FOR EX VIVO ORGAN CARE SYNKLINO A/S (DK) 2024-05-09 US claimed
CN-116570697-B Private care antibacterial gel based on plantain fruit extract 广西九绿药品有限公司 2024-02-06 CN claimed
WO-2024015366-A1 COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS Arkea Bio Corp. (US) 2024-01-18 WO claimed
CN-1292752-C Solutions containing epinastine BOEHRINGER INGELHEIM INT (DE) 2007-01-03 CN claimed
CN-1867344-A Pharmaceutical composition containing oxoplatin, salts and derivatives thereof SALAMA ZOSER B (DE) 2006-11-22 CN claimed
WO-2006096182-A1 AZITHROMYCIN POWDER FOR ORAL SUSPENSION COMPOSITIONS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2006-09-14 WO claimed
US-20060198895-A1 Azithromycin powder for oral suspension compositions TEVA PHARMACEUTICALS USA, LTD. 2006-09-07 US claimed
US-6814978-B2 HAVING A FRIABILITY OF LESS THAN ABOUT 2% FROM AN ACTIVE INGREDIENT, AN EXCIPIENT IN THE FORM OF A HYDRATE, AND A WATER- SWELLABLE EXCIPIENT; AND APPLYING ENERGY TO DECREASE THE HARDNESS OF THE TABLET BY AT LEAST 20%. MCNEIL-PPC, INC. 2004-11-09 US claimed
CN-1124386-C Adsorption-type solar water generator with air as raw material BINGSHAN GROUP CO LTD DALIAN (CN) 2003-10-15 CN claimed
US-20030175339-A1 Process for preparing a soft tablet BUNICK FRANK J (US) 2003-09-18 US claimed
US-20020122822-A1 Process for preparing a soft tablet JOHNSON & JOHNSON CONSUMER INC. 2002-09-05 US claimed
CN-1313434-A Adsorption-type solar water generator with air as raw material BINGSHAN GROUP CO LTD DALIAN (CN) 2001-09-19 CN claimed
US-5788990-A Water-repellent powder and manufacture of the same DOW CORNING TORAY SILICONE CO., LTD. (JP) 1998-08-04 US claimed